

Corrigendum

Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Brian Godman,^{1,2,3} Magdalene Wladysiuk,^{4,5} Stuart McTaggart,⁶ Amanj Kurdi,^{1,2,7} Eleonora Allocati,⁸ Mihajlo Jakovljevic^{ID},^{9,10,11} Francis Kalemeera,¹² Iris Hoxha,¹³ Anna Nachtnebel,¹⁴ Robert Sauermann,¹⁴ Manfred Hinteregger,¹⁴ Vanda Marković-Peković^{ID},¹⁵ Biljana Tubic,^{16,17} Guenka Petrova^{ID},¹⁸ Konstantin Tachkov,¹⁸ Juraj Slabý,¹⁹ Radka Nejezchlebova,¹⁹ Iva Selke Krulichová,²⁰ Ott Laius,²¹ Gisbert Selke,²² Irene Langner,²² András Harsanyi,²³ András Inotai^{ID},²⁴ Arianit Jakupi^{ID},²⁵ Svens Henkuzens,²⁶ Kristina Garuolienė^{ID},²⁷ Jolanta Gulbinovič^{ID},²⁷ Patricia Vella Bonanno,^{1,28} Jakub Rutkowski,⁵ Skule Ingeberg,²⁹ Øyvind Melien,²⁹ Ileana Mardare,³⁰ Jurij Fürst,³¹ Sean MacBride-Stewart,³² Carol Holmes,³³ Caridad Pontes,^{34,35} Corinne Zara,³⁴ Marta Turu Pedrola,³⁴ Mikael Hoffmann,³⁶ Vasileios Kourafalos,³⁷ Alice Pisana^{ID},³⁸ Rita Banzi^{ID},⁸ Stephen Campbell^{ID},^{39,40} and Bjorn Wettermark⁴¹

¹Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

²Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

³School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

⁴Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland

⁵HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland

⁶Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK

⁷Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

⁸Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy

⁹Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia

¹⁰Institute of Comparative Economic Studies, Hosei University Tokyo, Japan

¹¹Department of Global Health Economics and Policy, University of Kragujevac, Serbia

¹²Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia

¹³Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania

¹⁴Dachverband der Österreichischen Sozialversicherungen, Kundmannngasse 21, AT-1030 Vienna, Austria

¹⁵Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

¹⁶Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

¹⁷Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina

¹⁸Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria

¹⁹State Institute for Drug Control, Prague, Czech Republic

²⁰Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic

²¹State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia

²²Wissenschaftliches Institut der AOK (WiO), Rosenthaler Straße 31, 10178 Berlin, Germany

²³Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary

²⁴Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary

²⁵Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo

²⁶Independent Consultant, Riga, Latvia

- ²⁷Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- ²⁸Department of Health Services Management, University of Malta, Valletta, Malta
- ²⁹Medicines Committee, Oslo University Hospitals, Oslo, Norway
- ³⁰Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania
- ³¹Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia
- ³²Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK
- ³³NHS Lothian, Edinburgh, UK
- ³⁴Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain
- ³⁵Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain
- ³⁶NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden
- ³⁷National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece
- ³⁸Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
- ³⁹Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK
- ⁴⁰NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK
- ⁴¹Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden

Correspondence should be addressed to Brian Godman; brian.godman@strath.ac.uk

Received 8 August 2022; Accepted 8 August 2022; Published 7 April 2023

Copyright © 2023 Brian Godman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below.




FIGURE 3: Utilisation of insulin glargine 300 IU/ml (Gla-300) as a % of total insulin glargine (DDD based) across Europe over time.




FIGURE 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

References

[1] B. Godman, M. Wladysiuk, S. McTaggart et al., "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications," *BioMed Research International*, vol. 2021, Article ID 9996193, 16 pages, 2021.